Literature DB >> 31400325

Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer.

Jianyang Wang1, Zhouguang Hui2, Yu Men2, Jingjing Kang1, Xin Sun1, Lei Deng1, Yirui Zhai1, Wenqing Wang1, Nan Bi1, Jun Liang1, Jima Lv1, Zongmei Zhou1, Qinfu Feng1, Zefen Xiao1, Dongfu Chen1, Luhua Wang1, Jun Zhao3.   

Abstract

BACKGROUND: Systematic inflammation-immune status has been thought to play a crucial role in tumorigenesis and progress. This study evaluated the prognostic value of systematic inflammation-immune status in patients with resected non-small cell lung cancer with pathological N2 nodal involvement (pN2-NSCLC).
METHODS: The relation between the preoperative systematic inflammation-immune score (SIS), defined as preoperative peripheral platelet count × neutrophil count/lymphocyte count, and prognosis was tested in a retrospective study of 660 consecutive patients with completed resected pN2-NSCLC and validated by a prospective study of 189 patients enrolled (NCT00880971).
RESULTS: SIS of 650 × 109 was an optimal cutoff point to stratify the patients with pN2-NSCLC into high (>650 × 109) and low (≤650 × 109) SIS groups in the training cohort. Univariate and multivariate analyses revealed that the SIS was an independent predictor for overall survival, disease-free survival, and distant metastasis-free survival. In the validation group, high SIS (>650 × 109) predicted poor 5-year overall survival (hazard ratio [HR], 2.418; P = .006), disease-free survival (HR, 1.542; P = .042), and distant metastasis-free survival (HR, 1.682; P = .024). In addition to the number of positive lymph nodes, the area under the receiver operating characteristic curve of the SIS for outcomes was higher than the neutrophil count-to-lymphocyte count ratio, platelet count-to-lymphocyte count ratio, and other conventional clinicopathologic indices.
CONCLUSIONS: The preoperative SIS is a more sensitive survival predictor than most of the other conventional clinical indices and may aid in more accurately stratifying patients for risk assessment and treatment decision.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31400325     DOI: 10.1016/j.athoracsur.2019.06.035

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303.

Authors:  Takuro Miyazaki; Hisashi Saji; Hiroshige Nakamura; Takeshi Nagayasu; Norihito Okumura; Masanori Tsuchida; Makoto Sonobe; Keiju Aokage; Masayuki Nakao; Tomohiro Haruki; Morihito Okada; Kenji Suzuki; Masayuki Chida; Ichiro Yoshino
Journal:  Surg Today       Date:  2022-02-24       Impact factor: 2.540

2.  Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma.

Authors:  Qingpeng Zeng; Jiagen Li; Nan Sun; Qi Xue; Yushun Gao; Jun Zhao; Yousheng Mao; Juwei Mu; Dali Wang; Shugeng Gao; Jie He
Journal:  Transl Lung Cancer Res       Date:  2021-01

3.  Prognostic Value of Pretreated Blood Inflammatory Markers in Patients with Bone Sarcoma: A Meta-Analysis.

Authors:  Min Jiang; Shaowei Ma; Zhongyan Hua; Zhiying Zhao; Song Gao
Journal:  Dis Markers       Date:  2021-04-08       Impact factor: 3.434

4.  A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery.

Authors:  Kaiming Zhang; Liqin Ping; Xueqi Ou; Meiheban Bazhabayi; Xiangsheng Xiao
Journal:  J Pers Med       Date:  2021-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.